FADS2 and triple-negative breast carcinoma: FADS2 was found to be highly expressed in a subset of triple-negative breast cancer patients characterized by poorer prognoses 40; furthermore, donafenib was shown to downregulate FADS2, resulting in synergistic inhibition of hepatocellular carcinoma in both in vitro and in vivo models 41.